FORM PT	F PATE	ENTS AND OTHER IT	JRE STATEM	IENT	30727.0013.0 APPLICANT: METABASIS		09	RIAL N 9/518,5	01	
JUN 1 1 7	m A	lse several sheets i	f necessary)	#2	FILING DATE: March 5, 199		GF	ROUP: 614	, IIVC.	
704	L 1							/14		
TRAD'										
			U.S. P.	ATENT DOCU	IMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		IAME	CLAS	5	SUB CLASS		LING ATE
the	TAR	3,018,302	01.23.62	Bielefeld, e	t al.					716
	AB	5,157,027	10/20 92	Biller, et al.					1	
· W	AC	5,658,889	8/19/97	Gruber, et a	al.					
· ·										
			POREIGN	PATENT DO	CUMENTS			-		-
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COL	JNTRY			SUB	TRANSL	
an	AD	0 002 062 A	30.05.78	EP (Abstract		CLAS	<u> </u>	CLASS	YES	NO
	AE	0 072 531 A	23,02.83	EP (Abstract						
	AF	0 158 057 A	16.10.85	EP (Abstract						
	AG	0 180 276	28.12.88	EP						
	АН	0 261 283	22.09.86	EP						-
	AI	0 161 955 A	21.11.85	EPO						
	AJ	0 338 372 A	25.10.89	EPO						
	AK	0 353 692 A	07.02.90	EPO			1			
1	AL	0 481 214 A	22.04.92	EPO						
N/	AM	492 738 A	30.06.70	СН						
<u>V</u>	AN	16 93 219 ₁ A	17.09.70	DE (Abstract)	1					
EXAMINER:	TZ	0// m	Que	DATE	CONSIDÈRED:	491	0			
me moug	i citati	tial if reference is co	onsidered, wi	hether or not cit considered. In	ation is in confo	rmance this for	with m wit	MPEP h next	609; Dr	aw

FORM PT		•			ATTY. DOC 1 30727.0013.C	NO.			IAL NO	-	<u> </u>
LIST 0		NTS AND OTHER 11 MATION DISCLOSI			APPLICANT: METABASIS						
OIP	E JC,	se several sheets if	f necessary)		FILING DATE:		_	GRO	UP:	IIVC.	
	-M	ル \			March 5, 1999			1614	4		
IN		OFFICE OF	FOREIGN	PATENT DO	CUMENTS				****	-	
EXAMINER INITIAL	8 RADE		DATE						UB		LATION
MILL	1	DOCUMENT NUMBER	DATE	DE (and En	glish language	CL	ASS	<u>a</u> _	ASS	YES	NO
7	AO	35 12 781 A1	10.04.85	U.S. Patent	No. 4,952,740)						
	AP	96/01267 A	18.01.96	wo	···						
	Aà	97/03679 A	06.02.97	wo							
•	AR	98/09668 A	12.03.98	wo							
<u>. </u>	AS	98/39342	11.09.98	wo							
	AT	98/39343	11.09.98	wo /							
	AU	98/39344	11.09.98	wo							
								T			
	ОТН	ER DOCUMENTS	(Includin	g Author, Ti	tle, Date, Perti	nen	t Pa	iges	, etc.)	
gr	AV	"Patent Abstract (Yamishata Koji;	s of Japan," Nippon So	Vol. 1998, N da Co. Nd), 1	o. 1, 30 January 6 September 19	199 97	8 &	JP 0	9 24	1284 A	
	AW	DeLombaert, et a New Generation Chem. 37: 498-5	al., " <i>N-</i> Phos on of Neutra	phonomethyl	Dipeptides and	The	ir Ph .11)	ospl Inhit	nonat pitors,	e Prod J. Me	lrugs, d.
	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem.										
4	AX Res. Synop., 5: 122-123 (1989)										
	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)										
4	AZ	Farquhar, et al., 72(3): 3/24 (1983	"Biologically			ctive	Gro	pups	," <u>J. F</u>	harm.	Sci.
	Ģ		9/10	cal	05		-	`			
EXAMINER:	$\overline{\mathcal{A}}$	\bigcap	10	DATE	CONSIDERED:	1	1				

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw

line through citation if not in conformance and not considered. Include a copy of this form with next

FORM PTO-1449 ATTY. DOC r NO. SERIAL NO. 30727.0013.CIP1 09/518,501 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S APPLICANT: INFORMATION DISCLOSURE STATEMENT METABASIS THERAPEUTICS, INC. FILING DATE: **GROUP:** (Use several sheets if necessary) March 5, 1999 1614 THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) TA TRAD Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2 oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. &hem. 28: 1358-1361 (1985)BÀ Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Pluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983) BB Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38. 3193-3198 (1989) BC Hillers, et al., Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a BD Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984) BE Kryuchkov, et al. Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987) BF Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 BG (1984)Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986) BH Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," Bioorg. Med. Chem. BI Lett. 7: 99-104 (1977) Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979) BJ Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993) BK EXAMINER: DATE CONSIDERED: Examiner EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw

line through citation if not in conformance and hot considered. Include a copy of this form with next

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) ATTY. DOC T NO. 30727.0013.CIP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC. FILING DATE: March 5, 1999 1614

JUH 1 1	790	
A IR	BTH.	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
MARIA	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)
	ВМ	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
•	ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981)
	BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Str., 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1957-1864 (1994)
	B/S	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
U	ВТ	Zon, ét al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)
•	A	Il dollates

		
EXAMINER:		DATE CONSIDERED:
Examiner	Venn Mil	1/9/02
EXAMINER: I	initial if reference is considered, whether or	not citation is in conformance with MPEP 609; Draw
line through cita	ation if not in conformance and not consider	ed. Include a copy of this form with next
communication	to applicant	

•							•		
FORM PTC					30727.001	NO. IP1	SERIAL NO 09/518,50		
1				APPLICANT: METABASIS T	PEUTICS,	EUTICS, INC.			
ĦU	(Use several sheets if necessary)				FILING DATE: March 5, 1999		GROUP:		
	/	OIRE	•				_ <u>''\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</u>	<u> </u>	
	7	FEB 2 5 2002 5				>	MAR O	SVX	
	PART		U.S. PA	TENT DOC	JMENTS .	ECH	CENTER	2002	O _
EXAMINER INITIAL		DOCUMENT NUMBER	DAŢĖ		NAME	CLASS	CLI (FIL D/20 D	LING ATE
1CM	AA	3,018,302	01/23/62	Bielefeld, e	t al.	260	46	2300	
My	AB	5,157,027	10/20/92	Biller, et al.	,	514	167	<u>مــ</u>	
-ju	AC	5,658,889	8/19/97	Gruber, et	al.	514	43		<u>-</u>
			N.						
		•	FOREIGN	PATENT DO	CUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	α	DUNTRY	CLASS	SUB CLASS	TRANS YES	LATION NO
	-				dish language				1

			FOREIGN	PATENT DOCUMENTS				
EXAMINER				COLUMN TO V	CLACC	SUB	TRANSL	
INITIAL	AD	0 002 062 A1	30.05.79	EP (and English language - Abstract)	CLASS	CLASS	YES	NO
TU	/AE	0 072 531 A1	23.02.83	EP (and English language -Abstract)				
CM	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)				
	AG	0 180 276 A1	28.12.88	EP				
	AH	0 261 283 A1	22.09.86	EP				
	Al	0 161 955 A1	21.11.85	EPO				
	AJ	0 338 372 A2	25.10.89	EPO				
	AK	0 353 692 A2	07.02.90	EPO				
	AL	0 481 214 B1	22.04.92	EPO				
	AM	492 738	30.06.70	CH (and English language Abstract)				
\bigvee	AN	987,378	17.09.70	UK				

EXAMINER: DATE CONSIDERED: 8000 | STANDING | DATE CONSIDERED: 1 | STANDING | DATE CONSIDERED:

FCRM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets(f thecessary)

ATTY	. DOCK	NO.
3072	27.001	SIP1

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 GROUP: 1614

	_	PATE		PATENT DOCUMENTS			MA	R 0	VE
EXAMINER INITIAL		DOCUMENT NUMBER	MARY CELLY	COUNTRY	CLA	ss EC	SUB LASSA/	YKANSI YES	AOITA, OKSOO
M	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)			-///	YES 26	2900
	AP	96/01267	18.01.96	wo					
	AQ	97/03679	06.02.97	wo					
	AR	98/09668	12.03.98	wo					
	AS	98/39342	11.09.98	wo					
17	AT	98/39343	11.09.98	wo					
	AU	98/39344	11.09.98	wo					

	ОТН	IER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
p	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. Chem. 37: 498-511 (1994)
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)
V	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)

EXAMINER: Examiner	Barres CHM CX	19	DATE CONSIDERED:	glor
	Initial if reference is considered tation if not in conformance and n to applicant			

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT 5 2002 CO (Use several sheets if necessary) (Use several sheets if necessary) ATTY. DOCKST NO. 30727.001 IP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS/NO. 30727.001 IP1 09/518,501

		18UFFO
	OTH	IER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985)
	ВВ	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," <u>J. Med. Chem.</u> 26: 1153-1158 (1983)
	ВС	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'- Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," <u>J. Antimicrob. Chemotherap.</u> 14: 93-99 (1984)
	вн	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
	ВІ	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," <u>Bioorg. Med. Chem.</u> <u>Lett.</u> 7: 99-104 (1997)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979)
V	BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)

EXAMINER: Examiner MMG MG (DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whe line through citation if not in conformance and not communication to applicant	ther or not citation is in conformance with MPEP 609; Draw onsidered. Include a copy of this form with next

FORM PTO-1449

ATTY. DOCKET NO. 30727.001

SERIAL NO. 09/518,501

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMEND

APPLICANT:

METABASIS THERAPEUTIO

FILING DATE: March 5, 1999 **GROUP:** 1614

(Use several sheets if necessary) FEB 2 5 2002 2

	ОТН	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
N	W BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, No. 1979, Pages 53-61.
	ВМ	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
	BP ·	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin</u> , 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J. Med. Chem. 37: 1857-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
	ВТ	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

			<u></u>			
EXAMINER:		1///	/ .	DATE CONSIDERED:	[c.]	<i>~</i>
Examiner	MMAGI		1	7	9/_	
EVAMINED	Initial if reference	is considered	v/ whether or	not citation is in conform	nance w	rith MPEP 609

line through citation if not in conformance and not considered. Include a copy of this form with next

Please type a plus sign

FEB 2 5 2002

Approved for

PTO/SB/08A (08-00) augh 10/31/2002. OMB 0651-0031

FEB 2 5 ZIVIL ω .S. Patont and Trademark Office: (*) DEPARTMENT OF COMMERCE proofs are required to respond to a collection of information unless? contains a valid OMB control number

Under the Paperwork Reduction Act of 19 kg Substitute for form 1449A/PTO

	Substitut	te for form 144	9A/PTO	The MARIE	4	Co	mplete if Known	→	Į.
			. 51661.6	TRANKWAR!	Applicat	lon Number	09/518,501		.
in.	NFOR	MATION	N DISCLO	SUKE	Filing Da		March 3, 2000		الله الله
S	TATE	EMENT I	BY APPL	ICANT		med Inventor	Erion	Ma	
_	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				Group A		1624	SCL PA	1//
		(use as mai	ny sheets as n	ecessary)	Examine		T. McKenzie	Co	4. ()
		<u> </u>	- 		A 44	Dealest Number	030727.0013.CIP1	CAL	ν_{λ}
Sheet		1	of	2	Attorney	Docket Number	030727.0010.01111	Wind THE	1002
Sheet		1	of	2			030727.0010.011	180	1002 -
Sheet		1 U.S. Pate		U.S. PATE	NT DOCU	MENTS Date of Publication	of Pages, Co	olumns, Lines,	1800 1800
Sheet Examiner Initials*	Cite No.5	U.S. Pate	nt Document Kind Code ² (# known)	U.S. PATE Name of Pateritee of Cited Doc	NT DOCU	MENTS	of Pages, Co When Passage	N 180	1800 1800
• Examiner			nt Document Kind Code ²	Name of Patentee	NT DOCU	MENTS Date of Publication Cited Document	of Pages, Co When Passage	burns, Lines, a Relevant a or Relevant	900

			Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines. Where Relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code' (tf' known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Refevant Pigures Appear	Т
								\perp
								4

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
PW AA		Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
	AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy," Vol. 42, p. 1146-1150 (May 1998).	
V	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

Examiner Signature Cons McHc9	Date Considered	2/12/03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box \$\frac{3}{2}\$

TRADENA

PTO/SB/08A (08-00) Approved for Lor through 10/31/2002. OMB 0851-0031
Patent and Tradamark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no penting are required to re applied to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

	omplete if Known	ı	70		
Application Number	09/518,501		-		
Filing Date	March 5, 1999		he.		
First Named Inventor	Erion	JE	140		
Group Art Unit	1624	CHO	-0		
Examiner Name	T. McKenzie		11.		
Attorney Docket Number	030727.0013.CI	P1	Ep		

		NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1,3
TU	AE	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of Grapefruit Juice," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	
9	AF	Jounaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy," Cancer Research, Vol. 58, p. 4391- 4401 (Oct. 1, 1998).	
	-		
•			

		1 /	
Examiner Signature Duni	Date Considered	2/13/02	
	Lonsidered	12/12/03	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ype a plus sign (+) inside this box > +

Sheet

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known						
Application Number	09/518,501					
Filing Date	March 3, 2000	0				
First Named Inventor	Erion et al.	7 . (
Group Art Unit	1624	1/2				
Examiner Name	McKenzie, T.	647				
Attomey Docket Number	45198.00013.RCE (CIP1)	1//				

				U.S. PATENT DOCU	MENTS	
Examiner	Cite	U.S. Patent	Document	Name of Patenies or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
initials*	No.1	Number	Kind Code ² (<i>if known</i>)	of Cited Document	Cited Occument MM-OD-YYYY	Pessages or Relevant Figures Appear
90		6,054,587		Reddy et al.	04/25/00	
1		6,110,903		Kasibhatla et al.	08/29/00	,
		6,284,748		Dang et al.	09/04/01	
		6,294,672		Reddy et al.	09/25/01	
		6,312,662		Erion et al.	11/06/01	
		6,399,782		Kasibhatla et al.	06/04/02	
77		6,489,476		Dang et al.	12/03/02	
		T				

				FOREIGN P	ATENT DOCUMEN	ITS		
Exemine	Cite		Foreign Patent Document		Name of Patenice or	Date of Publication of	Pages, Columns, Lines, Where Relevant	1
Initials	No.1	Office'	Number ⁴	Kind Code' (If lown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T.
7	*****							

NON PATENT LITERATURE DOCUMENTS						
Exeminer initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
			Ì			
· · · · · · · · · · · · · · · · · · ·		,	†-			
			1			
		<u> </u>	1			

Examiner Om Mall & Date Considered 4/16/0-

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Frew line through citation is not in conformance and not considered. Include copy of this form with next conformance and not considered. Include copy of this form with next conformance and not considered.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

of

Sheet

PTO/SB/08A (08-00)

45198.00013.RCE

e type a plus sign (+) inside this box > + Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Kn wn 09/518,501 **Application Number** INFORMATION DISCLOSURE **Filing Date** March 3, 2000 STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1624 (use as many sheets as necessary) Examiner Name T. McKenzie

Attorney Docket Number

				U.S. PATENT DOCU	MENTS	
Examiner	Cite	U.S. Patent	Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,
initiats*	No.	Number	Kind Code ² (//.kmown)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	L					
	7					•

		• • •				

				FOREIGN PA	TENT DOCUMEN	TS		
Examiner	Cite		Foreign Patent Doc	umeni	Name of Patentee or	Date of Publication of	Pages, Cohumns, Lines,	
Initials	No.1	Office ³	Number*	Kind Code ⁾ (if lown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passagus or Relevant Figures Appear	1
							-	丅
1								

		NON PATENT LITERATURE DOCUMENTS	******
Examiner Initiats	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T³
	,	FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	
N	/	LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).	

Examiner Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 2 7

SATENIA TH

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** NFORMATION DISCLOSURE 09/518,501 March 3, 2000 **Filing Date** STATEMENT BY APPLICANT First Named Inventor Erion et al. Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** T. McKenzie of **Attorney Docket Number** 032465.00013.RCE (CIP1)

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Çile No.'	U.S. Patent Docume Number Kind (# kind)	_	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Retovant Figures Appear
···						

				FOREIGN PA	ATENT DOCUMEN	TS		
Exeminer	Cite		Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines	
Initials	No.'	Office,	Number ⁶	Kind Code* (if bnown)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1
		<u>ساسہ</u> ا						1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1,5
81		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," <u>Tetrahedron</u> , 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," <u>J. Chem. Soc., Perk. Trans. 1</u> , (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	,
Q		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examiner Signature	Date Consider	red 4/16/6/
		——————————————————————————————————————

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English tanguage Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number

Complete if Known

Application Number 09/518,501

Filing Date March 3, 2000

First Named Inventor Erion et al.

Group Art Unit 1624

Examiner Name T. McKenzie

Attorney Docket Number 032465,00013,RCE (CIP1)

C	- Au	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
4		Friis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic α-acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," <u>Euro. J. Pharm. Sci.</u> , 4:49-59 (1996).	
		Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from 1-Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	
		Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>JACS</u> , 79:430-436 (1957).	
		Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).	
	•	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
		Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med. Chem.</u> , 29:716-727 (1986).	
		McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
		Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," <u>J. Org. Chem.</u> , 42(9):1549-1555 (1977).	
		Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," <u>J.</u> Am. Chem. Soc., 112:6936-3942 (1990).	L
1		Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," <u>Tetrahedron</u> , 38(5):761-764 (1997).	

Examiner Signature Date Considered 4/18/00

*EXAMINER: Initial if reference considered, whether or not offstion is in conformance with MPEP 809. Down line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

FEB 2

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/518,501 NFORMATION DISCLOSURE March 3, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Erion et al. **Group Art Unit** 1624 (use as many sheets as necessary) Examiner Name T. McKenzie Attorney Docket Number of 032465.00013.RCE (CIP1)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
81		Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," <u>Biochem. Pharm.</u> , 45(8):1685-1694 (1993).	
1		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4-Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Examiner Signature On McClpn Date Considered 4/6/5/

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 809. Draw the through chation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-tetter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.